๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Bavarian Nordic A/S (CPH:BAVA)
Denmark flag Denmark ยท Delayed Price ยท Currency is DKK
243.40
-4.80 (-1.93%)
Nov 20, 2026, 11:11 AM CET

Bavarian Nordic Earnings Call Transcripts

Fiscal Year 2026

  • Nine-month revenue grew 2% reported and over 9% organically, with strong rabies-led Travel Health performance and near-35% EBITDA margin. FY2026 guidance was maintained; capacity, U.S. Vimkunya access and Public Preparedness order timing remain key considerations.

  • H1 2026 revenue exceeded DKK 3 billion with 35% EBITDA margin, driven by strong Travel Health and Public Preparedness growth. Full-year guidance was upgraded to DKK 5.7 billion revenue and 30% EBITDA margin, with a new DKK 750 million share buyback announced.

  • Q1 2026 saw revenue of DKK 1,058 million and a 16% EBITDA margin, with strong travel health growth and upgraded full-year guidance following a new BARDA contract. Travel health and public preparedness segments both contributed, and cash position remains robust.

Fiscal Year 2025

  • Revenue reached DKK 6.2 billion in 2025, with strong growth in travel health and public preparedness, and a 28% EBITDA margin. 2026 guidance anticipates DKK 5โ€“5.2 billion revenue and 25% EBITDA margin, with continued expansion in travel health and new agreements for chikungunya vaccine.

  • Revenue rose 32% year-over-year to DKK 4.8 billion, with strong growth in both travel health and public preparedness. EBITDA margin reached 31%, and full-year guidance is confirmed at DKK 6 billion revenue. Vimkunya launch and market share gains in key vaccines drive future growth.

  • Revenue grew 33% year-over-year in H1 2025, driven by strong vaccine sales and portfolio balance. EBITDA margin reached 32%, with improved gross margin and robust cash position. Guidance for 2025 was refined upward, and a recommended takeover offer was announced.

  • Strong revenue and margin growth were reported, driven by both travel health and public preparedness. New product launches, especially chikungunya, and ongoing innovation support future growth, while strategic M&A and a potential voucher sale could further boost financials.

  • Q1 saw 62% revenue growth and a 31% EBITDA margin, driven by strong travel health and public preparedness segments. Guidance for the year is maintained, with robust order books and new product launches supporting future growth.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020

Fiscal Year 2019

Fiscal Year 2018

Fiscal Year 2017